Two Of The Cyclos Share At Least Three Ring Members (i.e., Bridged) Patents (Class 514/214.03)
-
Patent number: 10695339Abstract: The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline salt and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period, the central nervous system disorder being selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline salt.Type: GrantFiled: June 18, 2019Date of Patent: June 30, 2020Assignee: PureTech Health LLCInventors: Eric Elenko, Philip E. Murray, III, Andrew C. Miller
-
Patent number: 10478440Abstract: The present invention provides a pharmaceutical composition for inhibiting angiogenesis containing a plant-derived natural compound which can be effective for preventing or treating disorders or diseases associated with angiogenesis. The compound used as an active ingredient in the pharmaceutical composition of the present invention suppresses VEGF-induced angiogenic responses without cytotoxicity at a low concentration by inhibiting the expression of an anti-angiogenic factor (for example, VEGF), and thus remarkably improves the safety of a drug.Type: GrantFiled: May 10, 2017Date of Patent: November 19, 2019Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITYInventors: Ho Jeong Kwon, Yong Hyo Kim
-
Patent number: 9782361Abstract: The present invention relates to the anti-convulsant activity of turmeric oil and its volatile bisabolene sesquiterpenoids ar- turmerone, ?-turmerone, ?-turmerone (curlone) and ?-atlantone, as an anticonvulsant agent for the treatment of epilepsy and/or as therapeutic agents for the treatment of disorders of the central nervous system, including tremor, pain, mood disorders (including depression, bipolar disorder, attention deficit-hyperactivity disorder, and schizophrenia), and neurodegenerative diseases.Type: GrantFiled: July 4, 2012Date of Patent: October 10, 2017Assignee: Katholieke Universiteit LeuvenInventors: Peter A. M. De Witte, Camila V. Esguerra, Alexander D. Crawford, Adriana Monserrath Orellana Paucar
-
Patent number: 9561233Abstract: This invention is directed to methods of treating pain in patients comprising treating patients with ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof at a therapeutic dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL.Type: GrantFiled: March 2, 2015Date of Patent: February 7, 2017Assignee: DEMERX, INC.Inventor: Lawrence Friedhoff
-
Patent number: 9492543Abstract: Disclosed herein is a pharmaceutical composition comprising a cholinesterase inhibitor and compound of the following formula: The composition is effective for treating cognitive disorders, and methods of treating such disorders using the composition are also disclosed.Type: GrantFiled: October 11, 2012Date of Patent: November 15, 2016Assignee: Allergan, Inc.Inventors: Ursula V. Staubli, John E. Donello
-
Patent number: 9394294Abstract: Disclosed are methods and compositions for purifying the non-addictive alkaloid noribogaine.Type: GrantFiled: June 6, 2014Date of Patent: July 19, 2016Assignee: DEMERX, INC.Inventors: Deborah C. Mash, Richard D. Gless, Jr.
-
Patent number: 9358237Abstract: Disclosed are noribogaine compositions comprising a very high level of the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer and not more than 0.5 wt % of ibogaine relative to the total amount of noribogaine.Type: GrantFiled: July 22, 2011Date of Patent: June 7, 2016Assignee: DEMERX, INC.Inventors: Robert M. Moriarty, Deborah C. Mash
-
Patent number: 9045468Abstract: The compounds of the present invention are represented by the following 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives having formula (I): where the carbon atom designated * is in the R or S configuration when n is 1 and the substituents X and R1-R7 are as defined herein.Type: GrantFiled: August 17, 2011Date of Patent: June 2, 2015Assignees: Albany Molecular Research, Inc., Bristol-Myers Squibb CompanyInventors: Peter R. Guzzo, Shuang Liu, Kristen N. Ryan, Bruce F. Molino, Russell DeOrazio, Richard E. Olson, John E. Macor
-
Patent number: 8993559Abstract: The present invention relates to a method of treating obesity in a subject by administering to the subject a compound having the formula: wherein n is from 0 to 8; R1 is CH2OH, CH(OH)R5, CH2OR5, CO2R5, C(O)NH2, C(O)NHR5, C(O)NR5R6, C(O)NHNH2, C(O)NHNHR5, C(O)NHNR5R6, C(O)NR5NH2, C(O)NR5NHR6, C(O)NR5NR6R7, C(O)NHNH(C(O)R5), C(O)NHNR5(C(O)R6), C(O)NR5NH(C(O)R6), C(O)NR5NR6(C(O)R7), CN, or C(O)R5; R2 is H, unsubstituted or substituted alkyl, YH, YR8, YR8R9, YR8YR9YR10, YC(O)R8, C(O)YR8, C(O)NH2, C(O)NHR8, C(O)NR8R9, NH2, NHR8, NR8R9, NHC(O)R8, or NR8C(O)R9; R3 and R4 are the same or different and are selected from the group consisting of H, halogens, unsubstituted or substituted alkyl, OH, OR10, NH2, NHR10, NR10R11, NHC(O)R10, or NR10C(O)R11; R5, R6, R7, R8, R9, R10, and R11 are the same or different and are selected from the group consisting of H, unsubstituted alkyl, substituted alkyl, unsubstituted aryl and substituted aryl; R12 is selected from the group consisting of H, unsubstituted alkyl, and substituType: GrantFiled: January 27, 2009Date of Patent: March 31, 2015Assignee: Albany Medical CollegeInventors: Stanley D. Glick, Isabelle M. Maisonneuve, Olga D. Taraschenko
-
Patent number: 8952029Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.Type: GrantFiled: April 29, 2013Date of Patent: February 10, 2015Assignee: Jazz Pharmaceuticals Ireland LimitedInventor: Mark Eller
-
Patent number: 8921355Abstract: Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.Type: GrantFiled: July 8, 2009Date of Patent: December 30, 2014Assignee: Janssen R & D IrelandInventors: Sandrine Marie Helene Vendeville, Pierre Jean-Marie Bernard Raboisson, Tse-I Lin, Abdellah Tahri, Katie Ingrid Eduard Amssoms
-
Patent number: 8883775Abstract: The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.Type: GrantFiled: October 25, 2011Date of Patent: November 11, 2014Assignee: Cascade Prodrug Inc.Inventors: John G. Curd, John F. W. Keana, Alshad S. Lalani, Paul B. Westberg, Bradford Goodwin, W. David Henner
-
Patent number: 8841289Abstract: The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by nicotinic acetylcholine receptors, such as schizophrenia and Alzheimer's disease.Type: GrantFiled: October 11, 2010Date of Patent: September 23, 2014Assignee: Merck Sharp & Dohme B.V.Inventors: Paul David Ratcliffe, Thomas Russell Clarkson, Fiona Jeremiah, John Kinnard Ferguson MacLean
-
Patent number: 8822489Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.Type: GrantFiled: February 27, 2013Date of Patent: September 2, 2014Assignee: Acura PharmaceuticalsInventors: Vijai Kumar, David Dixon, Divya Tewari, Dilip B. Wadgaonkar
-
Publication number: 20140221353Abstract: The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer.Type: ApplicationFiled: December 5, 2013Publication date: August 7, 2014Applicants: Affichem, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Philippe De Medina, Michael Paillasse, Marc Poirot, Sandrine Silvente-Poirot
-
Patent number: 8772306Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.Type: GrantFiled: April 29, 2013Date of Patent: July 8, 2014Assignee: Jazz Pharmaceuticals, Inc.Inventor: Mark Eller
-
Patent number: 8614209Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11?-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11?-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.Type: GrantFiled: September 13, 2012Date of Patent: December 24, 2013Assignee: The University of EdinburghInventors: Scott Peter Webster, Jonathan Robert Seckl, Brian Robert Walker, Peter Ward, Thomas David Pallin, Hazel Joan Dyke, Trevor Robert Perrior
-
Publication number: 20130266666Abstract: The present invention relates to the combination of PM01183 with several anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and/or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734 and PM00104, and the use of these combinations in the treatment of cancer.Type: ApplicationFiled: November 11, 2011Publication date: October 10, 2013Applicant: PHARMA MAR, S.A.Inventors: Victoria Moneo Ocaña, Gema Santamaría Núñez, Luis Francisco García Fernández, Carlos Maria Galmarini, María José Guillén Navarro, Pablo Manuel Avilés Marín
-
Publication number: 20130165426Abstract: Disclosed is a compound of Formula I or a salt thereof, in which X, X1, X2, R1, R2, and R3 are described herein. Also disclosed are pharmaceutical compositions and methods of using the compounds of Formula I to treat disorders mediated by melanocortin-4 receptors.Type: ApplicationFiled: July 5, 2011Publication date: June 27, 2013Applicant: UNIVERSITÉ DE MONTRÉALInventors: Réjean Ruel, Yves Chantigny, Anne Marinier, Patricia Rene, Michel Bouvier
-
Patent number: 8410292Abstract: Disclosed are englerins and derivatives (I) thereof useful in the treatment of a number of cancers, particularly renal cancer, as well as pharmaceutical compositions and method of treating a patient with the use of these derivatives. The englerins, for example Englerin A and Englerin B, can be isolated from the plant Phyllanthus engleri or produced by synthetic methods. An example of the englerin derivative is 2?-chloroenglerin A, which has the structure (II), wherein double bond ‘a’ is E, Z, or a mixture of E and Z.Type: GrantFiled: December 30, 2008Date of Patent: April 2, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John A. Beutler, Ranjala Ratnayake, David Covell, Tanya R. Johnson
-
Patent number: 8362008Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11?-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11?-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.Type: GrantFiled: December 11, 2008Date of Patent: January 29, 2013Assignee: The University Of EdinburghInventors: Scott Peter Webster, Jonathan Robert Seckl, Brian Robert Walker, Peter Ward, Thomas David Pallin, Hazel Joan Dyke, Trevor Robert Perrior
-
Publication number: 20120208796Abstract: The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by nicotinic acetylcholine receptors, such as schizophrenia and Alzheimer's disease.Type: ApplicationFiled: October 11, 2010Publication date: August 16, 2012Inventors: Paul David Ratcliffe, Thomas Russell Clarkson, Fiona Jeremiah, John Kinnard Ferguson MacLean
-
Publication number: 20120156219Abstract: The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.Type: ApplicationFiled: February 22, 2012Publication date: June 21, 2012Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Hiromu HABASHITA, Masaya KOKUBO, Shiro SHIBAYAMA, Hideaki TADA, Tatsuya TANIHIRO
-
Patent number: 8178524Abstract: The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.Type: GrantFiled: June 8, 2010Date of Patent: May 15, 2012Assignee: Demerx, Inc.Inventor: Deborah C. Mash
-
Publication number: 20120071463Abstract: 1H-Imidazo[4,5-c]quinolin-4-amines with a hydroxy, alkoxy, hydroxyalkoxy, or alkoxyalkoxy substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.Type: ApplicationFiled: November 29, 2011Publication date: March 22, 2012Inventors: Tushar A. Kshirsagar, Philip D. Heppner, Scott E. Langer
-
Publication number: 20120046271Abstract: The compounds of the present invention are represented by the following 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives having formula (I): where the carbon atom designated * is in the R or S configuration when n is 1 and the substituents X and R1-R7 are as defined herein.Type: ApplicationFiled: August 17, 2011Publication date: February 23, 2012Applicants: BRISTOL-MYERS SQUIBB COMPANY, ALBANY MOLECULAR RESEARCH, INC.Inventors: Peter R. GUZZO, Shuang LIU, Kristen N. RYAN, Bruce F. MOLINO, Russell DEORAZIO, Richard E. OLSON, John E. MACOR
-
Publication number: 20120035102Abstract: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.Type: ApplicationFiled: July 1, 2010Publication date: February 9, 2012Applicant: ALBANY MOLECULAR RESEARCH, INC.Inventors: Peter R. GUZZO, Matthew David SURMAN, Lei ZHU
-
Patent number: 7989438Abstract: A class of macrocyclic compounds of formula (I), wherein R7, A, Ar, B, D, F, M, Q1, Q2, W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.Type: GrantFiled: July 15, 2008Date of Patent: August 2, 2011Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpAInventors: Immacolata Conte, Joerg Habermann, Angela Mackay, Frank Narjes, Maria del Rosario Rico Ferreira, Ian Stansfield
-
Publication number: 20110160185Abstract: Pyrrolopyrimidine derivatives of Formula (I) that are useful as JAK3 kinase inhibitors.Type: ApplicationFiled: March 31, 2008Publication date: June 30, 2011Inventors: Jorge Salas Solana, Carmen Almansa Rosales, Robert Soliva Soliva, Montserrat Fontes Ustrell, Marc Vendrell Escobar
-
Publication number: 20110065683Abstract: The present invention relates to 1-alkyl-3-aniline-5-aryl-pyrazole derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I). The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulator having the capability to increase the efficacy of nicotinic receptor agonists.Type: ApplicationFiled: May 8, 2009Publication date: March 17, 2011Inventors: Johannes Wilhelmus John F. Thuring, Gregor James MacDonald, Wei Zhuang
-
Publication number: 20110059937Abstract: This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).Type: ApplicationFiled: November 12, 2010Publication date: March 10, 2011Inventor: Jakob Busch-Petersen
-
Publication number: 20110015178Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11?-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11?-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.Type: ApplicationFiled: March 13, 2009Publication date: January 20, 2011Applicant: THE UNIVERSITY OF EDINBURGHInventors: Scott Peter Webster, Jonathan Robert Seckl, Brian Robert Walker, Peter Ward, Thomas David Pallin, Hazel Joan Dyke, Trevor Robert Perrior
-
Publication number: 20110003739Abstract: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.Type: ApplicationFiled: July 1, 2010Publication date: January 6, 2011Applicant: ALBANY MOLECULAR RESEARCH, INC.Inventors: Peter R. GUZZO, Matthew David SURMAN, Lei ZHU
-
Publication number: 20100249105Abstract: The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.Type: ApplicationFiled: March 19, 2010Publication date: September 30, 2010Applicant: ABBOTT LABORATORIESInventors: Michael R. Schrimpf, Chih-Hung Lee, Tao Li, Gregory A. Gfesser, Kathleen H. Mortell, Ramin Faghih, Diana L. Nersesian, Kevin B. Sippy, William H. Bunnelle, Marc Scanio, Lei Shi, Murali Gopalakrishnan, Diana L. Donnelly-Roberts, Min Hu
-
Publication number: 20100240887Abstract: A safe pharmaceutical composition for treatment of cancer contains Homoharringtonine (HHT). The new methods of process for producing HHT include culture plant tissue and semisynthesis.Type: ApplicationFiled: March 23, 2009Publication date: September 23, 2010Inventor: Yaguang Liu
-
Publication number: 20100227851Abstract: Provided are novel use of an extract of Lycoris chejuensis or a compound isolated therefrom for inhibition of ?-amyloid production and/or prevention, improvement and/or treatment of a neurodegenerative disease, more specifically a ?-amyloid production inhibitor, and/or a composition for prevention or treatment of a neurodegenerative disease containing one or more kinds selected from the group consisting of an extract of Lycoris chejuensis, and/or dihydrolycoricidine, 2-methoxypancracine, lycoricidine, and/or lycoricidinol, as an active ingredient; a method for inhibiting ?-amyloid production, and/or preventing and/or treating a neurodegenerative disease using the same; and, a method for preparing the same.Type: ApplicationFiled: October 28, 2009Publication date: September 9, 2010Applicant: Korea Institute of Science and TechnologyInventors: Hyun-Ok Yang, Hak-Cheol Kwon, Jin-Soo Park, Sung-Kwon Chung, Myung-Soo Kim
-
Publication number: 20100197662Abstract: Disclosed is a compound useful as a type I 11?hydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R1 is optionally substituted cycloalkyl, optionally substituted cycloalkenyl or the like, One of R2 and R3 is a group of the formula: —C(?O)—Y—R4, wherein Y is —NR9— or the like, R4 is optionally substituted cycloalkyl or the like, R9 is hydrogen or optionally substituted alkyl, W is optionally substituted alkylene, The other is a group of the formula: —V—R5, wherein V is a bond, —O— or the like, R6 is hydrogen or optionally substituted alkyl, R5 is hydrogen, optionally substituted alkyl or the like, X is a bond, —S—, —SO— or the like, U is a bond or optionally substituted alkylene, R7 is hydrogen or optionally substituted alkyl, Z is —S—, —O— or —NR8—, R8 is hydrogen, optionally substituted alkyl or the like.Type: ApplicationFiled: June 6, 2006Publication date: August 5, 2010Applicant: Shionogi & Co., Ltd.Inventors: Tomoyuki Ogawa, Noriyuki Kurose, Satoru Tanaka, Koichi Nishi
-
Patent number: 7754710Abstract: The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.Type: GrantFiled: April 6, 2007Date of Patent: July 13, 2010Assignee: Novoneuron, Inc.Inventor: Deborah C. Mash
-
Publication number: 20100113420Abstract: Pyrrolopyrimidine derivatives of Formula (I) that are useful as JAK3 kinase inhibitors.Type: ApplicationFiled: March 31, 2008Publication date: May 6, 2010Inventors: Jorge Salas Solana, Carmen Almansa Rosales, Robert Soliva Soliva, Montserrat Fontes Ustrell, Marc Vendrell Escobar
-
Publication number: 20100105658Abstract: [Problems] Provided is a compound which has an antagonistic action on a muscarinic M3 receptor and is useful as an active ingredient of a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like. [Means for Solving Problems] The present inventors have made studies on a compound having an antagonistic action on the binding of a muscarinic M3 receptor, and they have found that an aza-bridged-ring compound or a salt thereof has an antagonistic action on the binding of a muscarinic M3 receptor, thereby completing the present invention. The aza-bridged-ring compound of the present invention has an antagonistic action on the binding of a muscarinic M3 receptor, and can be used as a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like.Type: ApplicationFiled: February 7, 2008Publication date: April 29, 2010Applicant: ASTELLAS PHARMA INC.Inventors: Shinya Nagashima, Toru Kontani, Hiroshi Nagata, Yuji Matsushima, Hisao Hamaguchi, Tadatsura Koshika
-
Patent number: 7683050Abstract: The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment of cancer and other aberrant cellular diseases. The invention also provides methods and compositions for antiparasitic, antifungal, antiviral and antibacterial treatments.Type: GrantFiled: August 1, 2006Date of Patent: March 23, 2010Assignee: Chemgenex Pharmaceuticals, Inc.Inventor: Dennis M. Brown
-
Patent number: 7678363Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.Type: GrantFiled: August 25, 2006Date of Patent: March 16, 2010Assignee: BrainCells IncInventors: Carrolee Barlow, Todd A. Carter, Kym I. Lorrain, Jammieson C. Pires, Andrew Morse, Dana Gitnick, Kai Treuner, Alex Broadhead
-
Patent number: 7674794Abstract: Compounds of formula (I) wherein n is 0, 1, or 2; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ?7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.Type: GrantFiled: November 15, 2006Date of Patent: March 9, 2010Assignee: Abbott LaboratoriesInventors: Jianguo Ji, Tao Li
-
Patent number: 7658939Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.Type: GrantFiled: November 4, 2003Date of Patent: February 9, 2010Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
-
Patent number: 7652010Abstract: Azabicyclo pyridazinyl compounds including azabicyclooctyl-pyridazinyl-oxy compounds, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile, the compounds may be used for the treatment of various diseases or disorders, including those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: GrantFiled: October 14, 2005Date of Patent: January 26, 2010Assignee: Neurosearch A/SInventors: Dan Peters, Daniel B. Timmermann, Gunnar M. Olsen, Elsebet Østergaard Nielsen, Tino Dyhring Jørgensen
-
Publication number: 20100009968Abstract: The use of substituted amides for modulating the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, of the general formula I. Their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11?HSDI and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.Type: ApplicationFiled: June 28, 2007Publication date: January 14, 2010Applicant: High Point Pharmaceuticals, LLCInventors: Soren Ebdrup, Henrik Sune Andersen
-
Publication number: 20090215747Abstract: This invention discloses and claims methods for inhibiting bacterial ?-lactamases and treating bacterial infections by inhibiting bacterial ?-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a ?-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a ?-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed.Type: ApplicationFiled: May 1, 2009Publication date: August 27, 2009Applicant: Aventis Pharma S.A.Inventors: Jozsef Aszodi, Claude Fromentin, Maxime Lampilas, David Alan Rowlands
-
Publication number: 20090203668Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof wherein W, L, R3, R3a, R3b and R4 are defined herein.Type: ApplicationFiled: April 16, 2009Publication date: August 13, 2009Inventors: James J. Li, Lawrence G. Hamann, Haixia Wang, Zheming Ruan, Christopher B. Cooper, Jun Li, Jeffrey A. Robi
-
Publication number: 20090163469Abstract: The present invention relates to compounds of formula I and its salts, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.Type: ApplicationFiled: December 18, 2008Publication date: June 25, 2009Inventors: Giorgio Caravatti, Robin Alec Fairhurst, Pascal Furet, Vito Guagnano, Patricia Imbach
-
Publication number: 20090131406Abstract: The present invention relates to cripowellins and synthetic derivatives thereof for treating diseases of man and also, in particular, to their use for preparing a medicament for treating cancer or other proliferative disorders in man and animal. Furthermore, the present invention relates to novel cripowellin derivatives and processes for their preparation.Type: ApplicationFiled: June 13, 2006Publication date: May 21, 2009Applicant: BAYER CROPSCIENCE AGInventors: Horst-Peter Antonicek, Robert Velten, Peter Jeschke